莱芒生物：代谢增强型CAR-T疗法 实现细胞治疗颠覆性突破

Core Insights - CAR-T cell therapy offers hope for patients with relapsed refractory hematologic malignancies, but traditional therapies face challenges such as high doses, expensive costs (over 1.2 million yuan per treatment), poor efficacy in solid tumors, and high risk of side effects [1] - Shenzhen Lyman Bio has developed a low-dose metabolically enhanced CAR-T cell therapy based on its innovative immune metabolic reprogramming technology, redefining industry standards in cell therapy [1] Group 1 - The company was co-founded by Professor Tang Li from EPFL and Dr. Guo Yugang, in collaboration with Jingtai Technology, and is currently in the clinical stage of developing innovative immune metabolic drugs [1] - The core technology, Meta10, significantly enhances T cell anti-exhaustion capabilities and the formation of stem-like immune memory cells, addressing T cell exhaustion at its source [1] - The company has received multiple accolades, including the "Disruptive Technology Innovation" key project under the 2025 National Key R&D Program and the "Honor Award" at a major competition, and is recognized as a "potential unicorn enterprise" in Shenzhen for 2025 [1] Group 2 - Based on the Meta10 technology platform, Lyman Bio has developed multiple core research pipelines, including metabolically enhanced CAR-T and TILs, with the CAR-T therapy showing a groundbreaking advantage of a dosage only one-thousandth of conventional commercial CAR-T [2] - As of October 2025, all over 20 patients with relapsed refractory leukemia/lymphoma enrolled in the first batch achieved complete remission (CR) without severe cytokine storm side effects during treatment [2] Group 3 - The company has made significant progress in expanding indications, including the first patient with systemic lupus erythematosus receiving treatment in March 2025, achieving complete remission without medication [4] - In April, the first patient with relapsed refractory chronic lymphocytic leukemia achieved complete remission, and in July, clinical studies for metabolically enhanced BCMA CAR-T for relapsed/refractory plasma cell tumors and IIT studies for advanced solid tumors were initiated [4] - The technology has significantly reduced the cost structure of cell therapy, with future treatment costs expected to drop below 300,000 yuan due to low-dose design and automation processes [4] Group 4 - Lyman Bio has established multiple pipelines, including metabolically enhanced IL-10 CAR-T, TCR-T, TILs, and IL-10-Fc fusion proteins, with the IL-10-Fc fusion protein showing a cure rate increase from 0% to 90% in various solid tumor models during preclinical studies [5] - The company aims to continue advancing clinical research for solid tumors and improve production processes to further reduce the total production cost of CAR-T, benefiting more patients [5]